Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
-
- STATUS
- Not Recruiting
-
- participants needed
- 220
-
- sponsor
- Pfizer
Updated on 22 July 2024
Summary
The study will assess the relative benefit of cabergoline vs carbidopa/levodopa therapy in treating nighttime problems of Parkinson Disease.
Description
The trial was terminated prematurely June 26, 2005 due to the inability to re-supply study drug for the planned number of subjects. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.
Details
| Condition | Parkinson Disease |
|---|---|
| Age | 18years - 80years |
| Treatment | cabergoline, controlled-release levodopa / carbidopa |
| Clinical Study Identifier | NCT00174239 |
| Sponsor | Pfizer |
| Last Modified on | 22 July 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.